Nandrolone adds 2.6 kg of lean mass in CKD, on evidence largely from the 1980s

Design

systematic review and meta-analysis of 15 randomised trials, RoB 2 and GRADE assessed

Population

adults with chronic kidney disease across trials published 1974-2021

Primary outcome

lean body mass, haemoglobin and haematocrit

Effect

lean body mass +2.63 kg (95% CI 1.60-3.65, 4 trials, n=125); haemoglobin +0.81 g/dL and haematocrit +3.12%, both very low certainty

Fifteen randomised trials of intramuscular nandrolone decanoate in adults with chronic kidney disease, published between 1974 and 2021, were pooled. Lean body mass increased by 2.63 kg (95% CI 1.60 to 3.65) across four trials with 125 patients. Haemoglobin rose by 0.81 g/dL across six trials with 239 patients, and haematocrit by 3.12% across seven trials with 198 patients, but both were graded very low certainty with substantial heterogeneity. Quality of life findings were inconsistent, and long-term safety data were sparse.

The date range explains most of this. Nandrolone was studied for anaemia in CKD before erythropoiesis-stimulating agents existed, and those trials answered a question that has since been answered better; the haematological result is a historical artefact rather than a live option. Anabolic steroids also carry hepatotoxicity, virilisation, dyslipidaemia and cardiovascular concerns that trials of this vintage were not designed to capture.

The lean mass finding is the part that is not obsolete, because protein-energy wasting and sarcopenia in dialysis patients remain largely untreated and there is nothing good to offer. A 2.63 kg gain is meaningful in that context. Whether it translates into function, falls, hospitalisation or survival is entirely unknown, and the authors call for contemporary trials rather than for use.

• Do not use nandrolone for anaemia in CKD - erythropoiesis-stimulating agents and iron answer that question
• Screen for protein-energy wasting and sarcopenia routinely; it is the problem this evidence points at
• Prioritise nutrition and resistance exercise, which have contemporary evidence behind them
• Note the absence of long-term safety data on anabolic steroids in this population
• Treat this as a case for a modern trial, not as a treatment option

Why it matters

Sarcopenia in dialysis has no established drug treatment, and this is the only signal in the literature - from trials that predate modern practice.

Don't overread it

Very low certainty on the haematological outcomes and no long-term safety data - this is a research question, not a therapy.

The statistics, in plain English

The lean mass estimate rests on four trials and 125 patients, which is a small base for a 2.63 kg claim even with an interval that excludes zero. The haematological results carry very low GRADE certainty, meaning the true effect could be substantially different in either direction - certainty grading asks how much to believe an estimate, which is a separate question from whether it reached significance. Trials from 1974 to 2021 also span an era in which the background management of CKD anaemia changed completely, so pooling them assumes a constancy of context that does not hold.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.